Pembrolizumab Plus Olaparib in LA-HNSCC

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · May 4, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, pembrolizumab and olaparib, in patients with a type of advanced head and neck cancer known as locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The main goal is to see if giving these drugs before and after standard treatment with chemotherapy and radiation can help improve outcomes for patients. While both drugs are already approved for treating head and neck cancer, they haven’t been tested together in this way yet.

To be eligible for the study, participants need to be at least 18 years old and have a specific type of advanced head and neck cancer that has been confirmed by a biopsy. They should not have received prior treatments for their cancer and should be in generally good health. Participants will undergo some tests and assessments throughout the study to monitor their progress. It’s important to note that the trial is currently recruiting individuals of all genders, and those interested should discuss their eligibility with their healthcare provider to learn more about what participation entails.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
• • 1. Age \>18 years on the day of signing the consent
• • 2. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
• • 3. Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee. The subject must be willing to consent to a mandatory pre-study biopsy unless sufficient archival tissue is available.
• • 4. Biopsy confirmed American Joint Committee on Cancer 8th Edition35 stage III-IV B oral cavity squamous cell carcinoma (SCC), p16-negative oropharyngeal SCC, stage III-IVB hypopharyngeal SCC, stage III-IVB laryngeal SCC -OR- HPV-associated oropharyngeal SCC (p16 positive or HPV-associated) T4 or N3 , T1-3 N2 or T3N0-1 with \>10 pack-year tobacco history
• • 5. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by imaging (CT/ PET) and is suitable for repeated assessment.
• • 6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• • 7. No prior curative attempts for this cancer (i.e., surgery, radiation, systemic therapy) and not currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of the study intervention. No evidence of metastatic disease (M0)
• • Exclusion Criteria
• • 1. Subjects with prior and concurrent malignancies of different tumor types whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the study drug are eligible with the following exception: Subjects with prior history of HNSCC treated \< 3 years to the date of consent.
• • 2. Cisplatin-ineligible as defined in the protocol.
• • 3. Severe, active medical comorbidity. Subjects are considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography scan or any psychiatric disorder that prohibits obtaining informed consent.
• • 4. Subjects unable to swallow orally administered medication prior to initiation of study treatment.
• • 5. Systemic glucocorticoids for any purpose other than to modulate symptoms from an event of clinical interest of suspected immunologic etiology